Frankfurt am Main

The trials here

What the 11 trials at this site are about, from their registry records.

Conditions

• Amyloidosis2 trials
• Chronic kidney disease2 trials
• Lung cancer2 trials
• Asthma1 trial
• Bladder cancer1 trial
• Chronic lymphocytic leukaemia1 trial
• Heart failure1 trial
• Metastatic breast cancer1 trial
• Triple-negative breast cancer1 trial

Phase

• Phase 34 trials
• Phase 22 trials

Status

• Active, not recruiting3 trials
• Not yet recruiting3 trials
• Recruiting3 trials
• Completed1 trial
• Terminated1 trial

Lead sponsor

• AstraZeneca10 trials
• Alexion Pharmaceuticals, Inc.1 trial

Running trials

• Recruiting

  A Phase III Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With CKD Stage 3b and 4 (BalanceD-CKD)

  NCT07624305· Phase 3· AstraZeneca· Source

  Contact: AstraZeneca Clinical AstraZeneca Clinical

• Recruiting

  An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC

  NCT07720284· Phase 3· AstraZeneca· Source

• Recruiting

  Retinal Fundus Imaging and OCT Imaging for Ocular Detection of ATTR-CM

  NCT07690436· AstraZeneca· Source

• Recruiting

  UmbREALung - A Retrospective and Prospective, Observational, Real World Multi-cohort Study of Patients With Non-small Cell Lung Cancer (NSCLC) Initiating Approved Drugs Developed by AZ or as Part of an AZ Alliance

  NCT06726720· AstraZeneca· Source

• Recruiting

  A Non-interventional, Prospective Study With Benralizumab

  NCT06422078· AstraZeneca· Source

• Recruiting

  Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis

  NCT06465810· AstraZeneca· Source

• Active, not recruiting

  Retention Rate of Acalabrutinib in a Non-interventional Setting

  NCT05645172· AstraZeneca· Source

• Active, not recruiting

  Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)

  NCT04784715· Phase 3· AstraZeneca· Source

• Active, not recruiting

  To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.

  NCT03330847· Phase 2· AstraZeneca· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Amyloidosis2 recruiting
• Asthma1 recruiting
• Bladder cancer1 recruiting
• Chronic kidney disease1 recruiting
• Heart failure1 recruiting
• Lung cancer1 recruiting

Closed trials

• Terminated

  ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE

  NCT05746559· Phase 3· Alexion Pharmaceuticals, Inc.· Source

• Completed

  A Global Study to Assess the Effects of MEDI4736 (Durvalumab) in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer

  NCT02087423· Phase 2· AstraZeneca· Source